Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Asset disposition
Quarterly results
Acq. announced
CC transcript
Employment agrmnt
Coll. bargaining agrmnt
Director departure

NOVELION THERAPEUTICS INC. (NVLNF) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/14/2020 8-K Quarterly results
06/12/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Press Release"
03/30/2020 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
02/13/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/21/2020 8-K Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...
Docs: "Novelion Therapeutics Confirms Commencement of Voluntary Liquidation VANCOUVER, British Columbia, January 16, 2020 – Novelion Therapeutics Inc. today announced that the implementation of the Company’ s voluntary liquidation commenced at 5:00 p.m. Pacific Time today, January 16, 2020 . As of the Effective Date, Alvarez & Marsal Canada Inc. was appointed liquidator and charged with overseeing all aspects of the Liquidation. Concurrent with the Liquidator’ s appointment: Michael Price, previously Executive Vice President, Chief Financial Officer and sole executive officer and employee of the Company, resigned his positions, and Michael Price, Suzanne Bruhn, and Stephen Sabba resigned as directors of the Company. Shareholders and other interested parties should visit www.alvarezandmarsal.com/n..."
01/21/2020 SC 13G/A NB Public Equity K/S reports a 9% stake in Novelion Therapeutics Inc.
01/15/2020 3 Form 3 - Initial statement of beneficial ownership of securities:
01/15/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/10/2020 SC 13G/A EdgePoint Investment Group Inc. reports a 18.7% stake in NOVELION THERAPEUTICS INC.
01/03/2020 8-K Quarterly results
12/17/2019 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
12/12/2019 4 STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.
Txns: Bought 5,202 shares @ $0.6916, valued at $3.6k
Bought 40 shares @ $0.69, valued at $27.6
Bought 1,000 shares @ $0.7, valued at $700
12/11/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Executive Vice President and Chief Financial Officer"
12/09/2019 4 STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.
Txns: Bought 5,160 shares @ $0.7, valued at $3.6k
Bought 40 shares @ $0.7, valued at $28
Bought 4,500 shares @ $0.7, valued at $3.2k
11/26/2019 4 STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.
Txns: Bought 89,845 shares @ $0.7461, valued at $67k
11/15/2019 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
11/05/2019 8-K Submission of Matters to a Vote of Security Holders, Other Events
10/16/2019 4 STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 4 on NOVELION THERAPEUTICS INC.
Txns: Bought 100,000 shares @ $0.649, valued at $64.9k
10/08/2019 8-K Quarterly results
10/08/2019 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/03/2019 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/03/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/03/2019 8-K Quarterly results
10/03/2019 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/02/2019 3 STONEPINE CAPITAL, L.P. (10% Owner) has filed a Form 3 on NOVELION THERAPEUTICS INC.
10/02/2019 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
09/27/2019 SC 13D/A Whitefort Capital Master Fund, LP reports a 1.5% stake in Novelion Therapeutics Inc.
09/27/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
09/26/2019 4 PRICE MICHAEL DENNIS (CFO) has filed a Form 4 on NOVELION THERAPEUTICS INC.
Txns: Paid exercise price by delivering 3,926 shares @ $0.76, valued at $3k
09/26/2019 4 Chan Barbara Y (See Remarks) has filed a Form 4 on NOVELION THERAPEUTICS INC.
Txns: Paid exercise price by delivering 1,688 shares @ $0.76, valued at $1.3k
09/25/2019 8-K Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; E...
09/25/2019 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/20/2019 PRE 14A Form PRE 14A - Other preliminary proxy statements:
09/20/2019 SC 13D/A Healthcare Value Capital, LLC reports a 7.4% stake in Novelion Therapeutics Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy